Sun Pharma announces USFDA approval for DOCEFREZTM for Injection

Emirates PharmaAdvertisement

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug

Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial.

This NDA provides for the use of DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial for locally

advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone

refractory metastatic prostate cancer

Emirates PharmaAdvertisement